Senators who want to stop brand drug companies from paying generics to stay off the market and introduced legislation Wednesday (Jan. 17) to ban the practice already are working on a compromise to head off a potential unintended consequence of the bill, a congressional source told FDA Week. The bill as it was introduced has the potential to halt all settlements between brand and generic companies because it would prohibit them from accepting anything of value.